Publications by authors named "S H Broderick"
With the publication of CALGB 140503, an increase in wedge resections for small, peripheral non-small cell lung cancer is expected; however, a relative paucity of data exists as to what defines a high quality oncologic wedge resection. The Thoracic Surgery Outcomes Research Network (ThORN), through expert discussion, guided by review of what limited data does exist, and through use of a modified Delphi process, provides these consensus statements defining an oncologically sound, high quality wedge resection. The statements are classified into five categories: 1) Preoperative Considerations 2) Technical Aspects 3) Lymph Node Assessment 4) Margin Assessment and 5) Tissue Handling by Pathology.
View Article and Find Full Text PDFPurpose: Neoadjuvant immune checkpoint blockade with nivolumab plus ipilimumab improves overall survival (OS) in non-small cell lung cancer (NSCLC); however, randomized data for resectable lung cancer are limited. We report results from the exploratory concurrently randomized nivolumab plus ipilimumab and chemotherapy arms of the international phase III CheckMate 816 trial.
Methods: Adults with stage IB-IIIA (American Joint Committee on Cancer seventh edition) resectable NSCLC received three cycles of nivolumab once every 2 weeks plus one cycle of ipilimumab or three cycles of chemotherapy (on day 1 or days 1 and 8 of each 3-week cycle) followed by surgery.
Article Synopsis
- Co-mutations of KRAS and STK11 genes in advanced non-small cell lung cancer (NSCLC) are linked to resistance against immune checkpoint blockade (ICB) therapies, although their impact in patients receiving neoadjuvant chemoimmunotherapy remains unclear.
- A study investigated how these gene mutations affect recurrence-free survival in resectable KRAS-mutated NSCLC, revealing that those with co-occurring STK11 mutations had a higher risk of recurrence compared to those without.
- Analysis of tumor-infiltrating T cells indicated that the presence of STK11 mutations altered T cell behavior, suggesting that certain T cell characteristics might hinder effective anti-tumor immune responses in patients with KRASmut/STK11
: Preclinical and clinical data indicate that chemoradiotherapy (CRT) in combination with checkpoint inhibitors may prime an anti-tumor immunological response in esophageal cancer. However, responses to neoadjuvant therapy can vary widely and the key biomarkers to determine response remain poorly understood. The fecal microbiome is a novel and potentially modifiable biomarker of immunotherapy response, and both fecal and tumor microbes have been found to associate with outcomes in esophageal cancer.
View Article and Find Full Text PDFBackground: The Society of Thoracic Surgeons (STS) General Thoracic Surgery Database (GTSD) has been used to develop risk models for patients undergoing pulmonary resection for cancer. Leveraging a contemporary and more inclusive cohort, this study sought to refine these models.
Methods: The study population consisted of adult patients in the STS GTSD who underwent pulmonary resection for cancer between 2015 and 2022.